
MindMed Unveils MM120 Phase 2b Study for GAD at APA Annual Meeting
MindMed (NASDAQ: MNMD), a clinical-stage biopharmaceutical company focused on developing innovative treatments for brain health disorders, unveiled data from its Phase 2b study of MM120 (lysergide d-tartrate) for treating Generalized Anxiety Disorder (GAD) in adults. The study, known as MMED008,…












